Abbisko Therapeutics Co., Ltd.
http://www.abbisko.com/#page1
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abbisko Therapeutics Co., Ltd.
Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug
Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.
US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?
It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbisko Therapeutics Co., Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice